Racetam derivative

Phenylpiracetam Hydrazide

Phenylpiracetam hydrazide has no human pharmacokinetic study identified in the searches; the app's 4-hour half-life is the parent compound's value used as a placeholder.

Anecdotal evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Phenylpiracetam Hydrazide after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

1

Overview

Sources in this part

  1. 1Vanhee et al., 2025

Phenylpiracetam hydrazide is listed in the app as a racetam derivative in the cognitive category, with the abbreviation PPH and the synonyms fonturacetam hydrazide and phenylpiracetam hydrazine. The app's notes describe it as a distinct chemical entity and not a formulation of phenylpiracetam. Those notes also state that a 2024 Japanese forensic study (Tanaka and colleagues) confirmed its structure by NMR and LC-QTOF-MS in nootropic powders sold online. The text of that paper was not available to quote, so this statement rests on the app's notes alone.

A 2025 market surveillance study by Vanhee and colleagues (Journal of Xenobiotics), run by official medicines control laboratories in Europe and Australia, lists parent phenylpiracetam in one sample as a "SF medicine" that is "not authorised for human use by any health authority in the EU or Australia".1 That table concerns phenylpiracetam, and the text of the paper contains no mention of the hydrazide.

2

How it works

Sources in this part

  1. 2Marlex Pharmaceuticals, 2026

The mechanism of phenylpiracetam hydrazide in people or animals has not been described in any source identified. The app's notes raise a concern drawn from chemical class: isoniazid, a hydrazide drug, is described there as depleting functional vitamin B6 and as associated in humans with hepatotoxicity, anaemia and peripheral neuropathy. The notes call this a class concern and not a demonstrated finding for this molecule. On pyridoxine, the label states that "deficiency is sometimes observed in adults with high doses of isoniazid and is considered probably due to its competition with pyridoxal phosphate for the enzyme apotryptophanase".2 That statement describes isoniazid, not phenylpiracetam hydrazide.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
90%
Typical dose
100–200 mg/dose
Route
Oral
Time to peak
~1.5 h

The app's notes state that every pharmacokinetic number for this compound is the parent compound phenylpiracetam's value used as a placeholder so a curve can be drawn, and that none has been measured for the hydrazide.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureSource figure for the hydrazide
Half-life~4 hNone identified
Bioavailability90%None identified
Time to peak~1.5 hNone identified
4

Doses reported in studies and on labels

The rows below are for the parent compound, phenylpiracetam, because no dose for the hydrazide was identified; they are not hydrazide doses. The app lists 100–200 mg/dose, while Vanhee and colleagues give the parent compound's typical pharmacological dosage per day (100–200 mg/day).1

Table 4.1Doses reported in studies and on labels2 rows
SourceCompoundDose reportedContext
Vanhee and colleagues, J Xenobiot 20251Phenylpiracetam (parent)100–200 mg/daySummary table of nootropics describing a "Prescription medication, available in Russia"; not a trial
NCT07852130, registry entry3Phenylpiracetam (parent)Oral 100, 200 or 300 mg/day before testingPlacebo-controlled, randomised, parallel design in 70 healthy volunteers aged 18 to 35, with 25 on an inert preparation and about nine per active compound; hydrazide not an arm
5

Bloodwork and markers

Sources in this part

  1. 2Marlex Pharmaceuticals, 2026

The app lists liver enzymes and serum B12 as markers to monitor and flags the compound as hepatotoxic. The app's notes give the reason as the class concern about hydrazides and name vitamin B6 status as well. The isoniazid label describes "mild and transient elevation of serum transaminase levels" in "10 to 20 percent of patients taking isoniazid", and "severe and sometimes fatal hepatitis" in a boxed warning.2 No measurement of liver enzymes, B6 or B12 in people exposed to phenylpiracetam hydrazide was identified.

6

Regulatory and anti-doping status

The WADA Prohibited List 2026 names "Fonturacetam" and "4-phenylpiracetam (carphedon)" in its stimulants class, which is "PROHIBITED IN-COMPETITION".4 Fonturacetam is listed under S6.A, non-specified stimulants; the list of specified stimulants (S6.B) ends with "and other substances with a similar chemical structure or similar biological effect(s)".4 The text of the 2026 list does not name the hydrazide. Jędrejko and colleagues (Drug Testing and Analysis, 2023) write that "The first nootropic prohibited in sport was fonturacetam (4-phenylpiracetam, carphedon) in 1998", and that some nootropics "may qualify as non-approved substances or related substances under catch-all language in the WADA Prohibited List".5 The app's notes say the hydrazide would plausibly fall under the related-substances catch-all; neither source examined here rules on it.

7

What is not known

No controlled or observational study of phenylpiracetam hydrazide in people was identified in PubMed or ClinicalTrials.gov. A ClinicalTrials.gov search for "phenylpiracetam" returned one entry, a registered trial of racetam-class compounds in healthy adults that lists the parent compound, "Drug: Phenylpiracetam", and no hydrazide arm.3 The registry entry names its lead sponsor and responsible party as the investigator Abdulraheem Mohamed Gouda (Reserology Research Foundation), and states that with approximately nine participants per active condition the study was designed to detect only very large effects.3 Absorption, metabolism, cognitive effect, safety and liver effects of the hydrazide are unmeasured in the sources identified. Cohen and colleagues (Neurology: Clinical Practice, 2021) report that phenylpiracetam, though labelled, was not detected in the supplements they tested.6

What is phenylpiracetam hydrazide?

It is a distinct chemical entity from phenylpiracetam, according to the app's notes. Its app category is racetam derivative.

Is there human data on phenylpiracetam hydrazide?

No human pharmacokinetic, efficacy or safety study of it was identified in PubMed or ClinicalTrials.gov.

What is the half-life of phenylpiracetam hydrazide?

The app lists about 4 hours, and no figure for the hydrazide was identified in the sources examined. The app's notes state this is the parent compound's value used as a placeholder.

Is phenylpiracetam hydrazide banned by WADA?

The 2026 WADA Prohibited List does not name phenylpiracetam hydrazide in the text searched, and it names fonturacetam (4-phenylpiracetam) among prohibited stimulants.4 The list of specified stimulants (S6.B) closes with a clause on substances of similar chemical structure or biological effect, and the app's notes say the hydrazide would plausibly fall under the related-substances catch-all.4

Why does the app flag liver enzymes for phenylpiracetam hydrazide?

The app's notes cite a chemical class concern from the hydrazide group, based on isoniazid, and not a finding for this molecule. The isoniazid label describes "mild and transient elevation of serum transaminase levels" in "10 to 20 percent of patients taking isoniazid", and separately reports that "Severe and sometimes fatal hepatitis associated with isoniazid therapy has been reported".2

Is phenylpiracetam hydrazide approved as a medicine?

No approval of it appears in the sources examined. Vanhee and colleagues state that the parent compound is not authorised for human use by any health authority in the EU or Australia.1

10

References

  1. Vanhee C, et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. J Xenobiot 2025. PMID 40558871
  2. Marlex Pharmaceuticals. Isoniazid tablets. US prescribing information, DailyMed record version 4, 2026. Isoniazid DailyMed label
  3. ClinicalTrials.gov. NCT07852130. Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity. Registry entry verified 2026-09. NCT07852130
  4. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  5. Jędrejko K, et al. Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Drug Test Anal 2023. PMID 37357012
  6. Cohen PA, et al. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurol Clin Pract 2021. PMID 34484905